Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Citigroup Maintains Neutral on Qualcomm, Raises Price Target to $132

Citigroup Maintains Neutral on Qualcomm, Raises Price Target to $132

Citigroup analyst Christopher Danely maintains Qualcomm (NASDAQ:QCOM) with a Neutral and raises the price target from $105 to $132.

byBenzinga Newsdesk

February 6, 2023

1 minute read

Citigroup analyst Christopher Danely maintains Qualcomm (NASDAQ:QCOM) with a Neutral and raises the price target from $105 to $132.

Wells Fargo Maintains Overweight on Lear, Lowers Price Target to $170

By Benzinga Newsdesk

July 11, 8:20 AM

Wells Fargo analyst Colin Langan maintains Lear (NYSE:LEA) with a Overweight and lowers the price target from $180 to $170.

LEA

Analyst Ratings

11 Analysts Assess Taysha Gene Therapies: What You Need To Know

By Benzinga Insights

April 30, 12:00 PM

Throughout the last three months, 11 analysts have evaluated Taysha Gene Therapies (NASDAQ:TSHA), offering a diverse set of…

TSHA

Peru’s Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details

By Lara Goldstein

September 21, 4:46 PM

Magdalena Biosciences, Jaguar Health (NASDAQ: JAGX) and Filament Health (OTCQB: FLHLF)

FLHLF

Europe Approves Sanofi, GSK’s Beta Variant Adapted COVID Shot As Booster

By Vandana Singh

November 10, 1:11 PM

The European Commission has approved Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE:GSK) partnered COVID-19 vaccine booster after the European Medicines Agency’s Committee for…

BNTX

Citigroup Maintains Neutral on Qualcomm, Raises Price Target to $132

Related Posts

Wells Fargo Maintains Overweight on Lear, Lowers Price Target to $170

11 Analysts Assess Taysha Gene Therapies: What You Need To Know

Peru’s Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details

Europe Approves Sanofi, GSK’s Beta Variant Adapted COVID Shot As Booster